San Francisco, United States
Ligandal is a biotechnology startup founded in 2014 and based in the United States. The company's slogan, "Ligandal is developing precision molecular therapeutics and targeted delivery technologies." reflects its core focus on genetic medicine and nanotechnology to develop personalized therapies. Ligandal is dedicated to developing ultra-rapid therapeutics and vaccines for outbreaks and pandemics, particularly focusing on immuno-oncology, rare genetic diseases, and currently, the development of a peptide-based cure for COVID-19 (SARS-CoV-2 coronavirus).
The company's expertise lies in targeted gene delivery, nano- and biomaterials, computational modeling of peptides, binding simulations, immunoengineering, as well as CRISPR and TALEN based gene editing. Notably, Ligandal focuses on combining gene therapy with targeting peptides to enable completely new paradigms in evolutionary medicine, thus paving the way for personalized medicine on a global scale through nanomedicine and gene therapies.
The most recent funding for Ligandal was a $1.80M Seed Round investment on 01 February 2019. The investors participating in this round are not specified.
In summary, Ligandal stands out as a promising player in the biotechnology sector, leveraging nanotechnology and genetic medicine to develop innovative therapies, with a current focus on addressing the COVID-19 pandemic through advanced peptide-based delivery technologies.
